SecBot SecBot
8-K ·Filed Aug 5, 2026

NAMS

NewAmsterdam Pharma Co N.V.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-333827
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The CHMP positive opinion is a transformative regulatory milestone that significantly increases the probability of European approval and Menarini-led launch in late 2026. Key upcoming catalysts: EC final decision, PREVAIL interim analysis (Q1 2027), RUBENS topline (YE 2026), and a potential Alzheimer's trial start. Monitor the Investor Day webcast for strategic details.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$27.42
T+0 close · Aug 5, 2026 · via day close
Latest settled
−24.29%
T+60 · $20.76
Vs SPY
−24.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $27.42entry
  2. T+1 · 3mo ago +0.91%α +1.07% · $27.67
  3. T+5 · 3mo ago +1.50%α +1.14% · $27.83
  4. T+20 · 3mo ago −6.67%α −6.07% · $25.59
  5. T+60 · 19d ago −24.29%α −24.23% · $20.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion recommending marketing authorization for obicetrapib (Ubeslo) and obicetrapib/ezetimibe FDC (Evlarco) in Europe, the most significant catalyst to date. Net loss widened to $64.1M from $17.4M a year ago on higher R&D costs and non-recurring Menarini milestone revenue in the prior-year period, but cash remains ample at $678.3M.

Key Facts

  • CHMP positive opinion for obicetrapib 10 mg and FDC with ezetimibe; European Commission decision expected in 2H26
  • Cash, cash equivalents and marketable securities of $678.3M at June 30, 2026
  • Net loss of $64.1M in Q2 2026 vs $17.4M in Q2 2025
  • Revenue of $3.7M vs $19.1M prior year (prior-year included $16.1M development cost contribution from Menarini)
  • PREVAIL interim analysis planned for Q4 2026 with result in Q1 2027
  • RUBENS Phase 3 topline data expected by year-end 2026
  • Investor Day held on August 5, 2026

Financial Impact

Positive CHMP opinion substantially de-risks European approval; potential peak sales in Europe for obicetrapib are not disclosed but the addressable market includes >30M under-treated patients in the U.S. alone. Near-term financials are secondary to regulatory and clinical milestones.

cashnet lossrevenue

Risk Factors

  • European Commission may not follow the CHMP recommendation, though this is rare
  • PREVAIL CVOT failure or underwhelming interim results could significantly impair the asset's value
  • Commercial execution risk if approved, despite Menarini partnership
  • Cash burn of ~$70M per six months provides runway but could necessitate future financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-333827
Document: nams-20260805.htm0001193125-26-333827
Document: 0001193125-26-333827-index-headers.html0001193125-26-333827
Document: 0001193125-26-333827-index.html0001193125-26-333827
Document: 0001193125-26-333827.txt0001193125-26-333827
8-K Data (Synthetic)0001193125-26-333827

Track record

8 reports on NAMS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
  2. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
  3. Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
  4. Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
  5. Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
  6. Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
  7. Jul 24, 202616w ago 8-K Bullish 7/10 Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
  8. Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026